Bortezomib (marketed as Velcade™ by Millennium Pharmaceuticals) is a "first-in-class" proteasome inhibitor. It is the best studied of a next generation of anti-myeloma drugs, and is also a potential treatment for plasma cell leukemia.

Bortezomib works by blocking the action of 26S proteasome, which is a multicatalytic enzyme whose function is to degrade abnormal or misfolded proteins targeted for destruction. There is emerging evidence that 26S proteasome plays a role in myeloma and lymphoma.

The Multiple Myeloma Research Foundation was responsible for a substantial amount of the funding for the development and testing of this drug.

More on [ Bortezomib ]

Bortezomib - Twitter Search

RT @Dicer1: Most of the anti-cancer drugs for targeted therapy have satanic names: imatinib, bortezomib, apatinib, belzebub, trastuzumab, bevacizumab.
EleniGulevska (Eleni) Fri, 30 Dec 2011 19:35:42 -0000
RT @Dicer1: Most of the anti-cancer drugs for targeted therapy have satanic names: imatinib, bortezomib, apatinib, belzebub, trastuzumab, bevacizumab.
Most of the anti-cancer drugs for targeted therapy have satanic names: imatinib, bortezomib, apatinib, belzebub, trastuzumab, bevacizumab.
Dicer1 (Goran Kungulovski) Fri, 30 Dec 2011 19:27:24 -0000
Most of the anti-cancer drugs for targeted therapy have satanic names: imatinib, bortezomib, apatinib, belzebub, trastuzumab, bevacizumab.
Bortezomib RSS feed